RAS mutation may be even more important than determining treatment options, according to MDAnderson

coloCan
coloCan Member Posts: 1,944 Member
edited July 2014 in Colorectal Cancer #1

www.mdanderson.org/publications/oncolog/ras-mutation-status-may-predict-outcomes-after-surgery-for-colorectal-cancer-liver-metastases-oncol

Direct link doesn't seem to work,but if you type in "ras mutation" in search box of page that appears, you'll get this interesting article,if so interested (key word:"MAY")

(something calledCH4987655 (Ro4987655) is a MEK inhibitor that may prove useful with Ras/Raf mutations,tho in early phase trial 

Also,MGD007 is starting to enroll people for trial......and its not named for James Bonds' unknown cousin)

 

 

Comments

  • coloCan
    coloCan Member Posts: 1,944 Member
    #2
    For those of you in Europe:

    a company named Xbiotech is starting to enroll people in a phase III study of something called "Xilonix"....FYI

    (again,FDA may be fast-tracking MGD007)

     

  • coloCan
    coloCan Member Posts: 1,944 Member
    #3
    coloCan said:

    For those of you in Europe:

    a company named Xbiotech is starting to enroll people in a phase III study of something called "Xilonix"....FYI

    (again,FDA may be fast-tracking MGD007)

     

    another antibody making its way thru trials is

    Sym004...................

    and here's something someone may find of interest onKRAS/NRAS mutations(interesting site too)

    www.mycancergenome.org/content/disease/colorectal-cancer/nras/316

    PS:Just came across this,a combo of cetuximab and trastuzumab

    http://onlinelibrary.wiley.com/doi/10.1111/cpr.12125/abstract

     

     

  • Quick2Listen
    Quick2Listen Member Posts: 1
    #4
    Kras mutation

    Although there are many genetic mutations classified as Kras + Tumors with mutated KRAS genes do not respond to treatment with cetuximab or panitumumab as yet

     

  • coloCan
    coloCan Member Posts: 1,944 Member
    #5
    Quick2Listen said:

    Kras mutation

    Although there are many genetic mutations classified as Kras + Tumors with mutated KRAS genes do not respond to treatment with cetuximab or panitumumab as yet

     

    Update on one potential,plus more on another:

    Supposedly good results thus far for Xilonix

    www.sys-con.com/node/3168361

    and phaae III starting for MGN 1703 (tho i think in Germany now)

    also,good news from phase iii on Ramucirumab........

Discussion Boards